Country: Canada
Language: English
Source: Health Canada
BUPROPION HYDROCHLORIDE
BAUSCH HEALTH, CANADA INC.
N06AX12
BUPROPION
150MG
TABLET (EXTENDED-RELEASE)
BUPROPION HYDROCHLORIDE 150MG
ORAL
250ML
Prescription
MISCELLANEOUS ANTIDEPRESSANTS
Active ingredient group (AIG) number: 0131140003; AHFS:
APPROVED
2001-07-04
_ _ _Pr_ _WELLBUTRIN_ _®_ _ SR, Bupropion Hydrochloride_ _Page 1 of 44_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR WELLBUTRIN SR Bupropion Hydrochloride Sustained-Release Tablets, 150 mg, for oral use Mfr. Std. ANTIDEPRESSANT Bausch Health, Canada Inc. Date of Initial Authorization: 2150 St-Elzear Blvd. West April 28, 1998 Laval, Quebec H7L 4A8 Date of Revision: July 18, 2022 Control #: 261888 _ _ _ _ _Pr_ _WELLBUTRIN_ _®_ _ SR, Bupropion Hydrochloride Page 2 of 44 _ _ _ _ _ RECENT MAJOR LABEL CHANGES 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 0/2022 7 WARNING AND PRECAUTIONS, Immune 01/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. TABLE OF CONTENTS .......................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION............................................................... 4 1 INDICATIONS.............................................................................................................. 4 1.1 Pediatrics ........................................................................................................... 4 1.2 Geriatrics............................................................................................................ 4 2 CONTRAINDICATIONS ............................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX...................................................... 5 4 DOSAGE AND ADMINISTRATION .............................................................................. 5 4.1 Dosing Considerations ........................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment .................................................... 5 4.4 Administration..................................................................................................... 6 4.5 Missed Dose................................... Read the complete document